Access cutting-edge prostate cancer treatment through this clinical trial at a research site in Chicago. Study-provided care at no cost to qualified participants.
Access prostate cancer specialists in Chicago at no cost
This study follows strict safety protocols and ethical guidelines
All study-related prostate cancer treatment provided free
Researchers conducting this study hope to learn about the safety and effectiveness of combining two study drugs, relacorilant and enzalutamide, plus androgen deprivation therapy (ADT), also known as hormone therapy. This study is for individuals who have been diagnosed with advanced, high-risk prostate cancer and standard therapies available to treat your disease have not been effective. Participation in this research will last about 3 years and 9 months.
Sponsor: University of Chicago
Check if you qualify for this prostate cancer clinical trial in Chicago, IL
If you're searching for prostate cancer treatment options in Chicago, IL, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Chicago research site is actively enrolling participants for this clinical trial. You'll receive care from experienced prostate cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.